At a flashy new research hub, AstraZeneca lays out ambitious growth goals; GSK’s asthma push continues as drug succeeds in Phase 3 trials

Taking stock of the drug industry, from the lab to the medicine chest

May 21, 2024 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Win McNamee/Getty Images STAT+ | At a flashy new research hub, AstraZeneca lays out ambitious growth goals The company is seeking to build on its momentum in fields like oncology as it said it would nearly double its revenue to $80 billion by 2030. By Andrew Joseph STAT+ | GSK's asthma push continues as drug succeeds in Phase 3 trials The drug, depemokimab, is designed to treat asthma by targeting a protein called interleukin-5, or IL-5. By Allison DeAngelis STAT+ | AltruBio raises $225 million to develop ulcerative colitis drug and other immune checkpoint enhancers AltruBio's $225 million Series B is the latest example of intense investor interest in immunology-focused companies. By Jonathan Wosen

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser